Skip to content

Discontinued — last reported Q2 '23

EBIT at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$39.05M+12.3%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.16M-5.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.67M-187%
Annexon logo
AnnexonANNX
-$46.05M+19.8%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Plus components not separately reported this period.

The official record: Omeros’s 10-Q, filed August 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about Omeros's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's EBIT?
Omeros (OMER) reported EBIT of -$40.9M in Q2 2023.
How has Omeros's EBIT changed year-over-year?
Omeros's EBIT decreased by 9.2% year-over-year, from -$37.44M to -$40.9M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.